Conditions: Colorectal Neoplasms
Keywords: GI neoplasms (phase 1)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 187
Healthy volunteers: no

Brief summary:
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.

Detailed description:

Arms:
arm 1: bevacizumab 5 mg/kg every 2 weeks + FOLFOX arm 2: AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX arm 3: AG-013736 5 mg bid starting dose + FOLFOX

Interventions: intervention 1: bevacizumab intervention 2: AG-013726 intervention 3: AG-013736 (axitinib)
Intervention descriptions: intervention 1: bevacizumab 5 mg/kg every 2 weeks intervention 2: AG-013726 5 mg bid every 2 weeks intervention 3: AG-013736 5 mg bid starting dose

Protocol document: